Back to top
more

BioXcel Therapeutics (BTAI)

(Delayed Data from NSDQ)

$2.63 USD

2.63
260,295

+0.02 (0.77%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.61 -0.02 (-0.76%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

BioXcel Therapeutics, Inc. [BTAI]

Reports for Purchase

Showing records 81 - 100 ( 107 total )

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 81

07/22/2019

Company Report

Pages: 5

BXCL501 Phase 1b Data Highly Favorable, Setting the Stage for Rapid Progress Into Pivotal Testing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 82

06/05/2019

Company Report

Pages: 5

Multiple Regulatory Milestones Achieved; Pipeline Progressing Rapidly; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 83

05/28/2019

Company Report

Pages: 5

1Q19 Financial Results Reported; R-D Day Event Showcases BXCL501 Development Scope; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 84

05/06/2019

Company Report

Pages: 5

BXCL501 Thin Film Formulation Process Development; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 85

03/26/2019

Company Report

Pages: 5

Positive AVP-786 Pivotal Data Draws Attention to BXCL501 in Alzheimer''s Disease-Related Agitation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 86

03/11/2019

Company Report

Pages: 4

2018 Financial Results Reported; Anticipating Further Clinical Progress in 2019; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 87

03/05/2019

Company Report

Pages: 5

Established Pharma Firms Join the Party; Triplet Regimen Slated for Assessment in Pancreatic Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 88

02/05/2019

Company Report

Pages: 6

Further Proof-of-Concept Data in Opioid Withdrawal; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 89

01/04/2019

Company Report

Pages: 5

Positive Proof-of-Concept Achieved in Alzheimer''s Patients; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 90

12/12/2018

Company Report

Pages: 4

BXCL501 Investigational New Drug Application Accepted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 91

12/05/2018

Company Report

Pages: 4

BXCL501 Proof-of-Concept Established; Healthy Cash Runway; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 92

10/31/2018

Company Report

Pages: 4

Poster Presentation at Upcoming Medical Meeting Announced; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 93

10/30/2018

Company Report

Pages: 4

BXCL501 Slated to Advance Into Clinical Testing Near-Term; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 94

10/08/2018

Company Report

Pages: 4

First BXCL701 Investigational New Drug Filing Submitted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 95

09/25/2018

Company Report

Pages: 4

Immuno-Oncology Partnership Expanded Into Clinical Development; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 96

09/19/2018

Company Report

Pages: 4

Translational Medicine, Clinical Pharmacology and Regulatory Affairs Head Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 97

09/05/2018

Company Report

Pages: 4

Head of Global Pharmaceutical Development and Operations Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 98

08/27/2018

Company Report

Pages: 5

Immuno-Oncology Clinical Advisory Board Established; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 99

08/09/2018

Company Report

Pages: 4

2Q18 Financial Results Reported; Significantly Lower-Than-Projected Spending; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Unclassified

Record: 100

08/01/2018

Company Report

Pages: 5

Business Development Head Appointed; Clinical Trial Milestones Approaching; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party